Oslo - Delayed Quote NOK
Nykode Therapeutics AS (NYKD.OL)
At close: November 7 at 4:25 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,147.0000
12,902.0000
7,168.0000
33,963.0000
215,000.0000
Operating Expense
64,999.0000
70,984.0000
60,324.0000
44,738.0000
36,738.0000
Operating Income
-58,852.0000
-58,082.0000
-53,156.0000
-10,775.0000
178,262.0000
Net Non Operating Interest Income Expense
7,929.0000
8,722.0000
3,309.0000
166.0000
-60.0000
Pretax Income
-47,806.0000
-44,086.0000
-50,983.0000
-11,118.0000
180,905.0000
Tax Provision
-9,892.0000
-8,932.0000
-8,240.0000
-1,704.0000
31,130.0000
Net Income Common Stockholders
-37,915.0000
-35,154.0000
-42,743.0000
-9,414.0000
149,774.0000
Diluted NI Available to Com Stockholders
-37,915.0000
-35,154.0000
-42,743.0000
-9,414.0000
149,774.0000
Basic EPS
-0.12
-0.12
-0.15
-0.03
0.54
Diluted EPS
-0.12
-0.12
-0.15
-0.03
0.51
Basic Average Shares
320,241.7930
300,520.3640
290,118.9810
286,344.8330
279,643.1650
Diluted Average Shares
320,241.7930
300,520.3640
290,118.9810
286,344.8330
296,145.2970
Total Operating Income as Reported
-58,852.0000
-58,082.0000
-53,156.0000
-10,775.0000
178,265.0000
Rent Expense Supplemental
--
933.0000
753.0000
665.0000
362.0000
Total Expenses
64,999.0000
70,984.0000
60,324.0000
44,738.0000
36,738.0000
Net Income from Continuing & Discontinued Operation
-37,915.0000
-35,154.0000
-42,743.0000
-9,414.0000
149,774.0000
Normalized Income
-37,915.0000
-35,154.0000
-42,828.5145
-9,511.3745
149,719.3572
Interest Income
8,145.0000
8,946.0000
3,687.0000
270.0000
198.0000
Interest Expense
216.0000
224.0000
241.0000
130.0000
46.0000
Net Interest Income
7,929.0000
8,722.0000
3,309.0000
166.0000
-60.0000
EBIT
-47,590.0000
-43,862.0000
-50,742.0000
-10,988.0000
180,951.0000
EBITDA
-45,337.0000
-41,740.0000
-48,928.0000
-10,253.0000
181,255.0000
Reconciled Depreciation
2,253.0000
2,122.0000
1,814.0000
734.0000
304.0000
Net Income from Continuing Operation Net Minority Interest
-37,915.0000
-35,154.0000
-42,743.0000
-9,414.0000
149,774.0000
Total Unusual Items Excluding Goodwill
--
--
102.0000
115.0000
66.0000
Total Unusual Items
--
--
102.0000
115.0000
66.0000
Normalized EBITDA
-45,337.0000
-41,740.0000
-49,030.0000
-10,368.0000
181,189.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
--
--
16.4855
17.6255
11.3572
12/31/2020 - 10/7/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ULTI.OL Ultimovacs ASA
1.8500
0.00%
7CA.BE Camurus AB
51.90
+1.37%
RVU.WA Ryvu Therapeutics S.A.
41.55
+4.66%
HPHA.DE Heidelberg Pharma AG
2.4000
-5.51%
MOLN.SW Molecular Partners AG
5.20
-6.14%
ALTME.PA TME Pharma N.V.
0.1432
+3.02%
ADOC.PA Adocia SA
8.69
+0.81%
FARN.L Faron Pharmaceuticals Oy
152.50
-3.17%
SIGHT.PA GenSight Biologics S.A.
0.3150
+0.80%
MDG1.DE Medigene AG
1.5420
-5.63%